The VA Will Now Pay For Fertility Treatment For Wounded Vets
By Merrit Kennedy,
NPR
| 09. 30. 2016
For the first time in almost 25 years, the U.S. Department of Veterans Affairs will pay for In Vitro Fertilization for wounded veterans.
As NPR's Quil Lawrence explains, Congress has reversed a law passed in 1992 that "prohibited the Department of Veterans Affairs from paying for IVF for veterans and their families." Quil tells our Newscast unit that "inside the stopgap spending bill passed this week is a provision to allow fertility treatments including IVF through VA health care." Here's more from Quil:
"Attempts to change that law have been blocked in recent years by opponents of abortion, since embryos are often destroyed in the IVF process.
"But political pressure has mounted as hundreds of Iraq and Afghanistan vets returned with blast wounds and other injuries that affect their reproductive abilities."
He adds that while the VA did not fund IVF for veterans until now, the Pentagon's health system did – for active duty troops who suffered "combat-related reproductive injuries."
The American Society for Reproductive Medicine says IVF costs an average of $12,400 per cycle, as Quil has reported...
Related Articles
By Grace Won, KQED [with CGS' Katie Hasson] | 12.02.2025
In the U.S., it’s illegal to edit genes in human embryos with the intention of creating a genetically engineered baby. But according to the Wall Street Journal, Bay Area startups are focused on just that. It wouldn’t be the first...
By Emma Cieslik, Ms. Magazine | 11.20.2025
Several recent Biopolitical Times posts (1, 2, 3, 4) have called attention to the alarmingly rapid commercialization of “designer baby” technologies: polygenic embryo screening (especially its use to purportedly screen for traits like intelligence), in vitro gametogenesis (lab-made eggs and sperm), and heritable genome editing (also termed embryo editing or reproductive gene editing). Those three, together with artificial wombs, have been dubbed the “Gattaca stack” by Brian Armstrong, CEO of the cryptocurrency company...
By Adam Feuerstein, Stat | 11.20.2025
The Food and Drug Administration was more than likely correct to reject Biohaven Pharmaceuticals’ treatment for spinocerebellar ataxia, a rare and debilitating neurodegenerative disease. At the very least, the decision announced Tuesday night was not a surprise to anyone paying attention. Approval...